Dr. Reddy’s Gets FDA Advertising Letter, But Its Response Is Far From Generic
This article was originally published in The Pink Sheet Daily
Despite changes to the website, the boxed warning about the risk of epidural or spinal hematomas for patients taking generic fondaparinux still receives little emphasis on a Dr. Reddy’s promotional page.
You may also be interested in...
FDA says a chart on Biogen Indec’s website implies Avonex is superior to Copaxone, Rebif, Betaseron and Extavia; the notice of violation was issued the same day FDA sent a warning letter to Teva citing its Copaxone promos.
In recent warning letters, FDA continued to hammer manufacturers for inadequate investigation of out-of-specification results and lax oversight of manufacturing operations by quality control units.
Bracco Diagnostics took down a promotional Web site in response to an untitled letter from DDMAC but disagrees that it hyped a study. GE Healthcare's Visipaque is cited in a separate letter.